CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Delta-9-tetrahydrocannabinol/cannabidiol

Last Updated: February 27, 2007
Result type: Reports
Project Number: SR0092-000
Product Line: Reimbursement Review

Generic Name: Delta-9-tetrahydrocannabinol/cannabidiol

Brand Name: Sativex

Manufacturer: GW Pharma Ltd.

Therapeutic Area: Pain, Neuropathic (adjunctive) in MS.

Indications: Pain, Neuropathic (adjunctive) in MS.

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: September 26, 2007

Recommendation Type: Do not list